reports
Cytokinetics Inc: 2 directors
Two Directors at Cytokinetics Inc sold 14,949 shares at between 65.380USD and 66.020USD. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FIL...
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and p...
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthc...
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 1:30 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at . The webcast replay will be archived on the...
PBF Energy Inc: 2 directors
Three Directors at PBF Energy Inc sold/sold after exercising options 431,026 shares at between 49.601USD and 51.660USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Downgrading Outlook to Bearish; Stay Defensive We are officially downgrading our outlook to bearish with the S&P 500 (SPX) violating major support at 6480-6520, Nasdaq futures (NQ) violating 24,000 support, and the Russell 2000 (IWM) breaking down below crucial $245 support. This comes after downgrading our outlook to neutral in our 3/3/26 Compass. Concerns that we discussed since early-February stemmed from deteriorating market dynamics, and ever since then we have been "concerned about a deep...
WLK WESTLAKE CHEMICAL CORPORATION
PSX PHILLIPS 66
PBF PBF ENERGY INC. CLASS A
OEC ORION ENGINEERED CARBONS SA
MUSA MURPHY USA INC.
KOP KOPPERS HOLDINGS INC.
INGR INGREDION INCORPORATED
GPRE GREEN PLAINS INC.
CVI CVR ENERGY INC.
CRESY CRESUD S.A.C.I.F. ADS
BAK BRASKEM S/A ADS
ANDE ANDERSONS INC.
ADM ARCHER-DANIELS-MIDLAND COMPANY
REX REX AMERICAN RESOURCES CORPORATION
MX. METHANEX CORPORATION
PARR PAR PACIFIC HOLDINGS INC
VLO VALERO ENERGY CORPORATION
DK DELEK US HOLDINGS INC
LND BRASILAGRO COMPANHIA BRASILEIRA DE PROPRIEDADES AGRICOLAS
ALTO ALTO INGREDIENTS INC
10JF SEBATA HOLDINGS LTD
DINO HOLLYFRONTIER CORP
BG BUNGE LIMITED
CLMT CALUMET INC
Ligand Advances Strategic Growth with Expanded and Strengthened Busine...
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development. Both will report to Paul Hadden, Ligand’s Senior Vice President of Investments and Business Development. Dr. Renehan comes to the firm from Blackstone Life Sciences, where he served as a Principal. He was previously in healthcare investment ba...
- Valens Research
PBF - Valens Credit Report - 2025 01 20
Credit markets are accurately stating credit risk with a YTW of 7.161% relative to an Intrinsic YTW of 6.947% and an Intrinsic CDS of 246bps. Meanwhile, Moody's is overstating the firm's fundamental credit risk, with its Ba2 credit rating four notches lower than Valens' IG4+ (Baa1) credit rating. Incentives Dictate Behavior™ analysis highlights mostly negative signals for credit holders. That said, as a positive, management members are material owners of PBF equity relative to their annual comp...
- Valens Research
PBF - Valens Credit Report - 2024 10 22
Credit markets are overstating credit risk with a YTW of 6.854% relative to an Intrinsic YTW of 5.794% and an Intrinsic CDS of 195bps. Furthermore, Moody's is overstating the firm's fundamental credit risk, with its Ba2 credit rating four notches lower than Valens' IG4+ (Baa1) credit rating. Incentives Dictate Behavior™ analysis highlights mixed signals for credit holders. That said, as a positive, management members are material owners of PBF equity relative to their annual compensation, indic...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,628 shares of common stock and 5,719 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in February and March 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the firs...
Gran Tierra Energy Inc. Announces Strategic Partnership with Ecopetrol...
Gran Tierra Energy Inc. Announces Strategic Partnership with Ecopetrol for The Development of Fields in the Middle Magdalena Valley Adjacent to Gran Tierra’s Largest Producing Field CALGARY, Alberta, March 17, 2026 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) is pleased to announce that it has signed a contract (collectively, “the Contract”) whereby the Company is expected to earn, subject to regulatory approvals and other conditions precedent, a 49 percent working interest (“WI”) in the Tisquirama block located in the ...
Gran Tierra Energy Inc. Provides AGM Update and Announces Board Change...
Gran Tierra Energy Inc. Provides AGM Update and Announces Board Changes CALGARY, Alberta, March 17, 2026 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE:GTE) announces that the Company has scheduled its 2026 Annual Meeting of Stockholders to be held on Friday, May 8, 2026, at 10:00 a.m. Mountain Time, 12:00 p.m. Eastern Time. Our Annual Meeting will be held as a virtual-only stockholder meeting with participation occurring electronically as explained further in our Proxy Statement. Shareholders will be able obtain a free copy...
Cytokinetics Announces Four Presentations at the American College of C...
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations related to MYQORZO™ (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place March 28–30, 2026 in New Orleans, LA. Recently approved for the treatment of adults with symptom...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Local Low in Place; Russell 2000 (IWM) Holds at $245 Our outlook as of last week (3/3/26 Compass) remains near-term neutral on the S&P 500 (SPX), after being bullish for all but one week since 4/22/25 (we went neutral 11/19/25-11/25/25). With that said, signs point to a local low being made yesterday after indexes went from heavily red, to firmly green as Trump signaled the war with Iran is nearing an end; Russell 2000 (IWM) held at 4+ year base support of $245, while S&P 500 futures (ES) held ...
PBF PBF ENERGY INC. CLASS A
MUSA MURPHY USA INC.
MPC MARATHON PETROLEUM CORPORATION
DLY LYONDELLBASELL INDUSTRIES NV
GPRE GREEN PLAINS INC.
CVI CVR ENERGY INC.
CF CF INDUSTRIES HOLDINGS INC.
ANDE ANDERSONS INC.
REX REX AMERICAN RESOURCES CORPORATION
PARR PAR PACIFIC HOLDINGS INC
VLO VALERO ENERGY CORPORATION
DK DELEK US HOLDINGS INC
NTR NUTRIEN LTD.
IPI INTREPID POTASH
ALTO ALTO INGREDIENTS INC
SOM SOMEC
UAN ARCADIAN PARTNERS LP PFD
Ligand Pharmaceuticals Inc: 2 directors
Two Directors at Ligand Pharmaceuticals Inc sold after exercising options/sold 18,423 shares at between 205.828USD and 206.354USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trad...
- Jonathan Moreland
RUN SUNRUN INC.
PYPL PAYPAL HOLDINGS INC
NMFC NEW MOUNTAIN FINANCE CORPORATION
GPK GRAPHIC PACKAGING HOLDING COMPANY
FMNB FARMERS NATIONAL BANC CORP.
DIN DINE BRANDS GLOBAL INC.
ACIW ACI WORLDWIDE INC.
WD WALKER & DUNLOP INC.
TTEC TELETECH HOLDINGS
AXR INC.
PCB AMREP
TSLX PACIFIC CITY FINANCIAL CORP
FOUR SIXTH STREET SPECIALTY LENDING
THRY INC.
EOSE SHIFT4 PAYMENTS
LUNG INC.
AIRS THRYV HOLDINGS
TTD EOS ENERGY ENTERPRISES INC (A)
FBRT PULMONX
BLCO AIRSCULPT TECHNOLOGIES INC
GTE THE TRADE DESK
EDSA FRANKLIN BSP REALTY TRUST INC
LAW BAUSCH + LOMB CORP
PMN GRAN TIERRA ENERGY INC.
EDESA BIOTECH INC
CS DISCO INC
PROMIS NEUROSCIENCES INC.
Ligand to Participate in March Investor Conferences
Ligand to Participate in March Investor Conferences JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 202638th Annual ROTH Conference (Dana Point, Calif.): Management will present at 1:00 p.m. PT on March 23, 2026Nordic-American Healthcare Conference 2026 (New York): Management will present at 3:45 p.m. ET on Mar...
Gran Tierra Energy Inc. Announces 2025 Fourth Quarter & Year-End Resul...
Gran Tierra Energy Inc. Announces 2025 Fourth Quarter & Year-End Results Achieved Average Working Interest Fourth Quarter Production of 46,344 BOEPDRealized 2025 Adjusted EBITDA1 of $284 MillionDelivered Net Cash Provided by Operating Activities of $313 Million, up 31% from 2024Generated 2025 Funds Flow from Operations1 of $178 MillionSeventh Consecutive Year of South American Reserves Growth With Over 100% Reserve Replacement PDP & 2PAchieved Company’s Best Safety Performance on Record in 2025Subsequent to Year-End Completed a Bond Exchange, Sold Non-Core Assets and Signed an Agreement in ...
Cytokinetics to Participate in March Investor Conferences
Cytokinetics to Participate in March Investor Conferences SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.2026 Jefferies Biotech on the Beach Summit: One-on-one m...
Gran Tierra Energy Inc. Announces Expiration and Final Results for the...
Gran Tierra Energy Inc. Announces Expiration and Final Results for the Previously Announced Exchange Offer of Certain Existing Notes for New Notes and the Solicitation of Consents to Proposed Amendments to the Existing Indenture CALGARY, Alberta, March 02, 2026 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today announced the expiration and final results of its previously announced offer to Eligible Holders (as defined herein) to exchange (such offer, the “Exchange Offer”) any and all of the Company’s outstanding 9.500% ...
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business update. Ligand man...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.